For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.
Faculty/Planner
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors
Jonathan A. Bernstein, MD - BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice
A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy
Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals
Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors
Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy
Richard K. Bogan, MD, FCCP, FAASM - Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment
Jennifer Wargo, MD, MMSc - New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy
Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal
Adam Friedman, MD, FAAD - Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, P
Leonard B. Bacharier, MD - Episode 4: What Are Our Most Significant Challenges in Treating Patients With Moderate to Severe Asthma and What Can We Learn From Each Other?
Arzu Yorgancioglu, MD - Episode 3: Uncontrolled Moderate to Severe Asthma in Pediatric and Adult Patients Around the World: Comparing Approaches to Treatment Selection
Klaus F. Rabe, MD, PhD, FERS - Episode 2: Which Patients Should Receive Targeted Biologic Therapy and When?
Leonard B. Bacharier, MD - Episode 1: Is Your Patient’s Moderate to Severe Asthma Uncontrolled? Global Approaches to Next Steps
Alok A. Khorana, MD, FACP, FASCO - REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism
Santosh L. Saraf, MD - Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions
R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management
Joshua B. Wechsler, MD, MSci - Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain